These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

488 related items for PubMed ID: 1617660

  • 21. DNA-binding properties of novel cis- and trans platinum-based anticancer agents in 2 human ovarian carcinoma cell lines.
    Mellish KJ, Barnard CF, Murrer BA, Kelland LR.
    Int J Cancer; 1995 Sep 15; 62(6):717-23. PubMed ID: 7558420
    [Abstract] [Full Text] [Related]

  • 22. Cellular pharmacology of liposomal cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum(II) in A2780/S and A2780/PDD cells.
    Han I, Ling YH, al-Baker S, Khokhar AR, Perez-Soler R.
    Cancer Res; 1993 Oct 15; 53(20):4913-9. PubMed ID: 8402681
    [Abstract] [Full Text] [Related]

  • 23. Novel trans platinum complexes: comparative in vitro and in vivo activity against platinum-sensitive and resistant murine tumours.
    Goddard PM, Orr RM, Valenti MR, Barnard CF, Murrer BA, Kelland LR, Harrap KR.
    Anticancer Res; 1996 Oct 15; 16(1):33-8. PubMed ID: 8615631
    [Abstract] [Full Text] [Related]

  • 24. Circumvention of platinum resistance: structure-activity relationship for homologous series of ammine/amine platinum(II) complexes in L1210 cell lines.
    Yoshida M, Khokhar AR, Siddik ZH.
    Anticancer Drug Des; 1994 Oct 15; 9(5):425-34. PubMed ID: 7945726
    [Abstract] [Full Text] [Related]

  • 25. New platinum, titanium, and ruthenium complexes with different patterns of DNA damage in rat ovarian tumor cells.
    Frühauf S, Zeller WJ.
    Cancer Res; 1991 Jun 01; 51(11):2943-8. PubMed ID: 2032232
    [Abstract] [Full Text] [Related]

  • 26. Modulation of cytotoxicity and cellular pharmacology of 1,2-diaminocyclohexane platinum (IV) complexes mediated by axial and equatorial ligands.
    Kido Y, Khokhar AR, al-Baker S, Siddik ZH.
    Cancer Res; 1993 Oct 01; 53(19):4567-72. PubMed ID: 8402629
    [Abstract] [Full Text] [Related]

  • 27. Sensitivity to novel platinum compounds of panels of human lung cancer cell lines with acquired and inherent resistance to cisplatin.
    Twentyman PR, Wright KA, Mistry P, Kelland LR, Murrer BA.
    Cancer Res; 1992 Oct 15; 52(20):5674-80. PubMed ID: 1327513
    [Abstract] [Full Text] [Related]

  • 28. Mini-review: discovery and development of platinum complexes designed to circumvent cisplatin resistance.
    Kelland LR, Sharp SY, O'Neill CF, Raynaud FI, Beale PJ, Judson IR.
    J Inorg Biochem; 1999 Oct 15; 77(1-2):111-5. PubMed ID: 10626362
    [Abstract] [Full Text] [Related]

  • 29. Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines.
    Mamenta EL, Poma EE, Kaufmann WK, Delmastro DA, Grady HL, Chaney SG.
    Cancer Res; 1994 Jul 01; 54(13):3500-5. PubMed ID: 8012973
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds.
    Meijer C, Mulder NH, Timmer-Bosscha H, Sluiter WJ, Meersma GJ, de Vries EG.
    Cancer Res; 1992 Dec 15; 52(24):6885-9. PubMed ID: 1458477
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Evaluation of novel ammine/amine platinum (IV) dicarboxylates in L1210 murine leukaemia cells sensitive and resistant to cisplatin, tetraplatin or carboplatin.
    Orr RM, O'Neill CF, Nicolson MC, Barnard CF, Murrer BA, Giandomenico CM, Vollano JF, Harrap KR.
    Br J Cancer; 1994 Sep 15; 70(3):415-20. PubMed ID: 8080724
    [Abstract] [Full Text] [Related]

  • 34. Tetravalent platinum complexes with ammine/amine carrier ligand configuration: circumvention of platinum resistance in vivo.
    Siddik ZH, Thai G, Yoshida M, Zhang YP, Khokhar AR.
    Anticancer Drug Des; 1994 Dec 15; 9(6):495-509. PubMed ID: 7880375
    [Abstract] [Full Text] [Related]

  • 35. Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues.
    Behrens BC, Hamilton TC, Masuda H, Grotzinger KR, Whang-Peng J, Louie KG, Knutsen T, McKoy WM, Young RC, Ozols RF.
    Cancer Res; 1987 Jan 15; 47(2):414-8. PubMed ID: 3539322
    [Abstract] [Full Text] [Related]

  • 36. Characterization of chemosensitivity and resistance of human cancer cell lines to platinum(II) versus platinum(IV) anticancer agents.
    Hamberger J, Liebeke M, Kaiser M, Bracht K, Olszewski U, Zeillinger R, Hamilton G, Braun D, Bednarski PJ.
    Anticancer Drugs; 2009 Aug 15; 20(7):559-72. PubMed ID: 19491657
    [Abstract] [Full Text] [Related]

  • 37. Induction and repair of DNA cross-links in chinese hamster ovary cells treated with various platinum coordination compounds in relation to platinum binding to DNA, cytotoxicity, mutagenicity, and antitumor activity.
    Plooy AC, van Dijk M, Lohman PH.
    Cancer Res; 1984 May 15; 44(5):2043-51. PubMed ID: 6538808
    [Abstract] [Full Text] [Related]

  • 38. Characterization of a human small cell lung carcinoma cell line with acquired resistance to cis-diamminedichloroplatinum(II) in vitro.
    Hospers GA, Mulder NH, de Jong B, de Ley L, Uges DR, Fichtinger-Schepman AM, Scheper RJ, de Vries EG.
    Cancer Res; 1988 Dec 01; 48(23):6803-7. PubMed ID: 2846161
    [Abstract] [Full Text] [Related]

  • 39. Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin.
    Samimi G, Kishimoto S, Manorek G, Breaux JK, Howell SB.
    Cancer Chemother Pharmacol; 2007 Feb 01; 59(3):301-12. PubMed ID: 16770583
    [Abstract] [Full Text] [Related]

  • 40. Effects of a piperidine ligand on DNA modification by antitumor cisplatin analogues.
    Kasparkova J, Novakova O, Najajreh Y, Gibson D, Perez JM, Brabec V.
    Chem Res Toxicol; 2003 Nov 01; 16(11):1424-32. PubMed ID: 14615968
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 25.